Free Trial

Metagenomi (MGX) Stock Forecast & Price Target

$6.38
-0.01 (-0.16%)
(As of 05/31/2024 ET)

Metagenomi - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Price Target

$17.83
179.52% Upside
High Forecast$25.00
Average Forecast$17.83
Low Forecast$6.00
TypeCurrent Forecast
6/2/23 to 6/1/24
1 Month Ago
5/3/23 to 5/2/24
3 Months Ago
3/4/23 to 3/3/24
1 Year Ago
6/2/22 to 6/2/23
Consensus Rating
Moderate Buy
Moderate Buy
N/AN/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A N/A
Buy
6 Buy rating(s)
5 Buy rating(s)
N/A N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
N/A N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A N/A
Consensus Price Target$17.83$19.40N/AN/A
Forecasted Upside179.52% Upside78.80% UpsideN/AN/A
Get Metagenomi Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.

MGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Metagenomi Stock vs. The Competition

TypeMetagenomiMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.70
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside179.52% Upside783.14% Upside9.91% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/15/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00+50.15%
5/2/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$16.00 ➝ $6.00-14.77%
3/28/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$21.00+89.36%
3/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
3/5/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$22.00+82.72%
3/5/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$23.00+91.03%
3/5/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$25.00+107.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:34 AM ET.

MGX Frequently Asked Questions

What is Metagenomi's stock forecast and purchase recommendation?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Metagenomi is $17.83, with a high forecast of $25.00 and a low forecast of $6.00. The consensus rating for Metagenomi stock is Moderate Buy based on the current 1 hold rating and 6 buy ratings for MGX. Learn more on MGX's analyst rating history.

Do Wall Street analysts like Metagenomi more than its competitors?

Analysts like Metagenomi more than other "medical" companies. The consensus rating score for Metagenomi is 2.86 while the average consensus rating score for "medical" companies is 2.70. Learn more on how MGX compares to other companies.

Is Metagenomi being downgraded by Wall Street analysts?

Over the previous 90 days, Metagenomi's stock had 1 downgrade by analysts.

Does Metagenomi's stock price have much upside?

According to analysts, Metagenomi's stock has a predicted upside of 75.67% based on their 12-month stock forecasts.

What analysts cover Metagenomi?

Metagenomi has been rated by research analysts at BMO Capital Markets, Chardan Capital, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., TD Cowen, and Wells Fargo & Company in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:MGX) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners